Fierce Biotech17h
Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
Stockhead on MSN11h
Crucible: This rare blood disease tackler plans to hit investors with its best shot
The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...
Dr Boreham’s Crucible: This rare blood disease tackler aims to hit investors with its best shot
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...
Pfizer has a new playbook for reviving sales—and it’s starting to pay off
The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...
Mint10h
Glaxosmithkline Pharmaceuticals share price
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.